Our study, incorporating the latest research and novel GLP‐1 RA‐based drugs, provides robust evidence for the cardiovascular benefits of GLP‐1 RA‐based therapies in overweight and obese populations without diabetes. This evidence concerns the gene GCG and diabetes mellitus.